written on 28.05.2014

Valeant adds cash and a CVR to its Allergan bid, but will that $50M-plus be enough?


As promised, Valeant has raised its original $47 billion offer for Allergan. And as expected, that offer comprises more cash than the original. Whether it'll be enough to win over the California company? That remains to be seen.

Latest Reports